Wordt geladen...
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Blinatumomab, the first-in-class CD3/CD19 bispecific T-cell engager antibody construct, has recently been approved for treating patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia. However, the clinical proof of concept of blinatumomab efficacy was initially demonstrated i...
Bewaard in:
| Gepubliceerd in: | Blood Adv |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6712531/ https://ncbi.nlm.nih.gov/pubmed/31451445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000025 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|